Floatz logo

lmp1/2 ctls

Lymphoepithelioma

Catherine BollardCell therapyPhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Lymphoepithelioma cohort.

Asset / SponsorPhaseRating
Anti-EGFR Antibody-drug Conjugate MRG003
Sun Yat-sen University
Phase 1CC
Gefetinib
National Cancer Institute (NCI)
N/ANR

Same molecule, other indications

lmp1/2 ctls is also rated in:

Hodgkins lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
leiomyosarcomaDormant
CCC
Indicative ·
48 / 100
View asset →
Severe Chronic Active EBV Infection Syndrome (SCAEBV)Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →